Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Top Page
Gossamer Bio
(NASDAQ:GOSS)
Rating:35Underperform
Price Target:―
Positive Factors
Clinical Trials
Gossamer completed enrollment in the PROSERA trial with 390 functional class II and III PAH patients, exceeding the original 350-patient target, reflecting strong demand and investigator enthusiasm.
Drug Development
Seralutinib's upcoming pivotal readout could be transformational for PAH patients, paving the way for Gossamer's first blockbuster opportunity.
Strategic Partnerships
The strategic partnership with Chiesi and Gossamer's $212.9 million cash position are key drivers toward a successful commercial launch for seralutinib in PAH, if approved.
Negative Factors
Clinical Data
GOSS hit an unexpected snag when Phase 2 week 24 topline data reported fell below investor expectations due to enrolling patients with milder disease severity.
Timeline Delays
Topline data for the PROSERA study is now expected in February 2026, causing a delay that may disappoint investors.
Gossamer Bio (GOSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$438.84M
Dividend YieldN/A
Average Volume (3M)2.87M
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-58.02%
EPS Growth-57.23%
CountryUS
Employees144
SectorHealthcare
Sector Strength43
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding227,380,620
10 Day Avg. Volume3,312,808
30 Day Avg. Volume2,869,213
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue6.70
Enterprise Value/Gross Profit6.70
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$9.20Price Target Upside369.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Gossamer Bio Business Overview & Revenue Model
Company DescriptionGossamer Bio (GOSS) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology. The company operates primarily in the biotechnology sector and is dedicated to advancing its pipeline of drug candidates designed to address unmet medical needs. Gossamer Bio's core products and services revolve around its innovative research and development efforts, aimed at creating effective treatments for serious diseases.
How the Company Makes MoneyGossamer Bio makes money primarily through the development and eventual commercialization of its proprietary therapeutic candidates. The company's revenue model is heavily reliant on the successful progression of its drug candidates through clinical trials, followed by regulatory approval and market entry. Key revenue streams include potential milestone payments, licensing agreements, and royalties from partnerships with larger pharmaceutical companies. Additionally, Gossamer Bio may generate income through strategic collaborations that provide funding for research and development activities, as well as potential future sales of approved drugs. The company's earnings are significantly influenced by the successful navigation of the regulatory landscape and the potential market demand for its therapies upon approval.
Gossamer Bio Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q1-2025)
| % Change Since: -9.26%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call presents a balanced view with significant achievements in study enrollment and strategic partnerships, but it is tempered by financial challenges and delays in study results. The financial position is strong, yet there is an increased R&D expense and a net loss. The sentiment is mixed, reflecting both optimism about Seralutinib's potential and concerns about financial and operational timelines.Q1-2025 Updates
Positive Updates
PROSERA Study Enrollment Success
Gossamer Bio achieved a significant milestone by nearing the completion of enrollment for the PROSERA study with 343 patients. The baseline characteristics of the patients are exactly as targeted, enhancing the likelihood of success.
Strong Financial Position
Gossamer Bio ended the quarter with $257.9 million in cash and cash equivalents, providing sufficient capital until the first half of 2027.
Potential Global Expansion
Seralutinib's potential for regulatory approval in Japan is supported by its orphan drug designation and participation of Japanese patients in the PROSERA study.
Strategic Partnership with Chiesi Group
The collaboration with Chiesi Group enables Seralutinib to immediately enter a global registrational Phase III study for PH-ILD, with a shared cost basis of 50-50.
Negative Updates
Delayed Data Release for PROSERA
The top line results of the PROSERA study are now anticipated in February 2026, due to the decision to honor commitments to patients currently in screening.
Increased R&D Expenses
R&D expenses for Q1 2025 were $38 million, compared to $32.4 million for the same period in 2024, indicating increased spending on research and development.
Net Loss for the Quarter
Gossamer Bio reported a net loss of $36.6 million, or $0.16 per share, for the quarter ended March 31, 2025.
Company Guidance
During the Gossamer Bio Q1 2025 earnings call, significant guidance was provided on the progress of Seralutinib, particularly in the Phase III PROSERA study for pulmonary arterial hypertension (PAH). The company achieved a milestone by closing new patient screenings with 343 patients enrolled or scheduled to randomize, while targeting a demonstration of a significant treatment effect in the six-minute walk distance at 24 weeks. The study aims to complete by the fourth quarter, with top-line results expected in February 2026. The baseline characteristics of the enrolled patients, including a mean six-minute walk distance of 376 meters and an NT-proBNP level of 96 ng/L, align with targeted criteria to optimize treatment success. Additionally, 74% of enrolled patients are categorized as functional Class III, indicating a sicker population likely to show a more dramatic improvement. The company emphasized Seralutinib's potential for first-in-class treatment, leveraging its unique mechanism and promising safety profile to position it as a backbone therapy in PAH. Financially, Gossamer ended Q1 with $257.9 million in cash, projecting sufficient funds until the first half of 2027.Gossamer Bio Financial Statement Overview
Summary
Gossamer Bio faces significant financial challenges, with high leverage and consistent losses. The recent revenue growth is a positive sign, but profitability and cash flow need substantial improvement to enhance financial health and stability.Income Statement
Gossamer Bio showed a significant revenue increase in 2024, but the company remains unprofitable with negative net income, EBIT, and EBITDA margins. The gross profit margin is nonexistent in prior years due to no revenue, indicating historical financial struggles.20
Very Negative
Balance Sheet
The company has a very high debt-to-equity ratio and negative equity in previous years, suggesting high financial leverage and risk. While equity became positive in 2024, it remains minimal compared to total liabilities, indicating ongoing financial instability.15
Very Negative
Cash Flow
Operating cash flow is consistently negative, reflecting poor cash generation relative to net income. However, the significant improvement in free cash flow in 2024 suggests efforts to stabilize cash flow, although it remains negative.25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.24M | 114.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 40.24M | 114.70M | -4.38M | -4.43M | -5.17M | -4.27M |
| EBITDA | -128.59M | -39.97M | -172.15M | -211.07M | -209.32M | -233.96M |
| Net Income | -138.74M | -56.53M | -179.82M | -240.23M | -249.08M | -251.58M |
Balance Sheet | ||||||
| Total Assets | 240.93M | 315.29M | 311.92M | 272.45M | 343.66M | 539.43M |
| Cash, Cash Equivalents and Short-Term Investments | 212.92M | 294.52M | 296.43M | 255.68M | 325.22M | 512.63M |
| Total Debt | 202.83M | 202.88M | 212.46M | 225.74M | 185.24M | 183.73M |
| Total Liabilities | 287.03M | 285.80M | 249.15M | 260.37M | 222.19M | 218.75M |
| Stockholders Equity | -46.11M | 29.49M | 62.77M | 12.08M | -811.53M | -577.53M |
Cash Flow | ||||||
| Free Cash Flow | -154.38M | -3.47M | -159.16M | -187.51M | -190.51M | -201.24M |
| Operating Cash Flow | -154.30M | -3.47M | -159.16M | -187.03M | -188.89M | -176.36M |
| Investing Cash Flow | 92.65M | 29.02M | -110.97M | -1.03M | -117.43M | 215.34M |
| Financing Cash Flow | 879.00K | -11.49M | 190.15M | 117.09M | 3.33M | 312.54M |
Gossamer Bio Technical Analysis
Positive
1.96
Price Trends
1.56
Positive
1.30
Positive
1.14
Positive
Market Momentum
0.11
Positive
58.40
Neutral
51.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOSS, the sentiment is Positive. The current price of 1.96 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.56, and above the 200-day MA of 1.14, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 58.40 is Neutral, neither overbought nor oversold. The STOCH value of 51.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GOSS.
Gossamer Bio Risk Analysis
Gossamer Bio disclosed 78 risk factors in its most recent earnings report. Gossamer Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gossamer Bio Peers Comparison
Overall Rating
UnderperformOutperform
Sector (47)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $438.36M | ― | -51.84% | ― | -100.00% | -25.75% | |
51 Neutral | $243.15M | ― | -31.16% | ― | ― | 15.14% | |
47 Neutral | $276.96M | ― | -32.38% | ― | ― | 23.24% | |
47 Neutral | C$212.51M | -2.12 | -24.82% | 3.10% | 19.48% | -0.09% | |
45 Neutral | $571.45M | ― | -35.02% | ― | ― | 20.37% | |
38 Underperform | $261.12M | ― | -66.13% | ― | ― | 19.76% | |
35 Underperform | $438.84M | ― | -783.37% | ― | -58.02% | -57.23% |
* Healthcare Sector Average
Performance Comparison
GOSS
Gossamer Bio
1.96
1.14
139.02%
IMMP
Immutep
1.72
-0.45
-20.74%
ANNX
Annexon Biosciences
2.38
-3.60
-60.20%
AVIR
Atea Pharmaceuticals
3.49
-0.25
-6.68%
CMPX
Compass Therapeutics
2.95
1.79
154.31%
TERN
Terns Pharmaceuticals
6.77
0.05
0.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.